Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+

It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA 74 PsA patients on GLP-1RA vs 74 matched controls (BMI + disease activity matched) After adjusting for BMI change PROs still improve cDAPSA (-0.4/mo) DAPSA (-0.6/mo) and pain but not SJC, TJC or CRP https://t.co/dcaU2jwbKJ

• https://x.com/AurelieRheumo/status/2062218873886384253/photo/1

Izokibep IL-17A Affibody PsA 343 pts RCT PBO crossover wk16 52 wks data ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52% No diff between QW vs Q2W AE Injection-site reactions, URTIs most common No new safety signals Looks like any other IL17Ai to me #EULAR2026 #OP073 https://t.co/WiHT8Plitn

• https://x.com/AurelieRheumo/status/2062215108231663736/photo/1

Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY

• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1

At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu

• https://x.com/synovialjoints/status/2062211485212832125/photo/1

Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886

• https://x.com/synovialjoints/status/2062210281942417906/photo/1

22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

• https://x.com/synovialjoints/status/2062208390512660905/photo/1

DIPSA RCT: diet in PsA 92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice Primary takeaway: amount of weight loss matters more than diet! -All groups lost modest weight 1–2.5 kg -All improved similarly in DAPSA -4 to -6 wk 24 -No differences for disease https://t.co/U0cxtdl2Yb

• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1
• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1
• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1

#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6

• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1

68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis 15 pts 1020 joints 35% affected joints clinically silent PET signal correlation w/ disease burden: DAPSA (ρ=0.66) CRP (ρ=0.69) Pilot study — not confirmed with US Needs validation but intriguing signal #OP068 https://t.co/nhS7PDZN0A

• https://x.com/AurelieRheumo/status/2062204893079716105/photo/1
• https://x.com/AurelieRheumo/status/2062204893079716105/photo/1

Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn

• https://x.com/JihaRheum/status/2062204122376343556/photo/1

TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn

• https://x.com/synovialjoints/status/2062204022908432498/photo/1

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y

• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1
• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1
• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1